The extent of intratumor heterogeneity and how treatment affects clonal evolution of cancer is an emerging theme in the field of cancer biology. In the era of targeted therapy, the presence of pre-existing treatmentresistant subclones within the tumor is a critical barrier to achieving durable responses. |